Compare 8x8 Inc (EGHT) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs 22nd Century Group Inc — how do they compare? 8x8 Inc trades at $1.93 (market cap $279.31M), while 22nd Century Group Inc trades at $4.27 (market cap $1.52M). The key difference: 8x8 Inc is far larger — about 183.8× 22nd Century Group Inc's market cap. Which is the better fit depends on your goals.
| EGHT | XXII | |
|---|---|---|
Market Cap | $279.31M | $1.52M |
Sector | Technology | Technology |
52-Week High | $2.76 | $1.47K |
52-Week Low | $1.59 | $3.90 |
Enterprise Value | $556.99M | -$6.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT (8x8, Inc.) trades at $1.89, down 12.9% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $27.21M in 2025 despite revenue of $715.07M, though recent quarters have beaten EPS estimates. Positive news includes AI product launches and industry awards, while analyst consensus is mixed with 39% buy ratings.
Outlook hinges on profitability improvement; projected net income of $2M in 2026 offers potential upside, but high debt and thin margins pose risks. Stock sentiment is cautiously optimistic due to innovation, yet volatility and competitive pressures require monitoring for sustained growth.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
